Live Peer-to-Peer Virtual Networking Session on September 9, 2024 from 4:00-5:00 CST
This module explores key considerations for the use of long-acting injectable (LAI) medications in inpatient settings and during transitions of care. Participants will review evidence supporting the earlier use of LAIs in treating schizophrenia and bipolar disorder and examine the pharmacist's role in ensuring continuity of care. Strategies to overcome barriers that may disrupt the LAI injection schedule during transitions will be discussed, along with approaches to engage patients and family members in shared decision-making. By the end of this session, learners will be equipped to optimize LAI use, improve adherence, and enhance treatment outcomes through effective care coordination.
This activity includes a 0.5-hour pre-recorded presentation and a 1-hour live, peer-to-peer virtual networking session. This is one of six modules in the Advanced Track Psychotropic Long-Acting Injectable Program. Complete your complimentary registration now to access this module and 5 other ACPE approved modules.
Target Audience
We invite you to participate in this online course if you are a pharmacist, nurse, or other health care professional interested in administering and/or learning more about psychotropic long-acting injectables for patients living with serious mental illness or substance use disorders.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
Learning Objectives
- Discuss evidence to support the earlier use of LAIs in the treatment of patients with schizophrenia or bipolar disorder.
- Describe how pharmacists can assist with LAI administration and continuity during transitions of care.
- Identify strategies that address barriers to maintaining the LAI injection schedule during transitions of care.
- Explain how to involve patients and family members in shared decision making to create treatment goals and improve adherence.
Continuing Education Credit and Disclosures
Activity Dates: 09/09/2024 - 12/31/2025
ACPE Contact Hours: 1
ACPE Number: 0284-0000-24-051-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Aristada, Abilify Maintena, Invega Sustenna injections
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.